Literature DB >> 6124670

Mechanism of reduced amyloid-A-degrading activity in serum of patients with secondary amyloidosis.

C P Maury, A M Teppo.   

Abstract

Human serum contains amyloid-A-degrading (AADP) activity. This activity is reduced in amyloidosis associated with rheumatoid arthritis. Since AADP co-migrates with albumin on agarose-gel electrophoresis, the relationship between these serum factors was studied in patients with amyloidosis and patients with amyloidosis and patients with altered albumin synthesis and/or distribution. AADP activity correlated positively with albumin levels in patients with rheumatoid arthritis complicated by amyloidosis. A weaker association was noted between serum activity and prealbumin levels. The AADP activity in patients with rheumatoid arthritis without signs of amyloidosis and patients with liver cirrhosis was also positively associated with serum albumin level. During the acute-phase reaction after surgery serum AADP activity fell in parallel with serum albumin level. Purified albumin preparations displayed AADP activity. The results show that serum albumin level reflects AADP activity. It is suggested that the development of hypoalbuminaemia in patients with amyloidosis may give rise to a vicious circle which leads to an accelerated reduction in AADP activity and accelerated amyloidogenesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124670     DOI: 10.1016/s0140-6736(82)90322-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.

Authors:  Tadashi Nakamura; Syu-ichi Higashi; Kunihiko Tomoda; Michishi Tsukano; Masahiro Shono
Journal:  Clin Rheumatol       Date:  2010-05-05       Impact factor: 2.980

Review 2.  Reactive (secondary) amyloidosis and its pathogenesis.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

Review 3.  Familial Mediterranean fever--an update.

Authors:  S E Goldfinger
Journal:  Trans Am Clin Climatol Assoc       Date:  1987

4.  Amyloid deposits in aortic and mitral valves. A clinicopathological investigation of material from 100 consecutive heart valve operations.

Authors:  C Ladefoged; N Rohr
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

5.  Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes.

Authors:  K Migita; S Yamasaki; K Shibatomi; H Ida; M Kita; A Kawakami; K Eguchi
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

6.  Antibodies to amyloid A protein in rheumatic diseases.

Authors:  C P Maury; A M Teppo
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

7.  'Amyloid degrading activity' of human serum, an in vitro clearing effect which does not involve degradation of amyloid fibrils.

Authors:  D Caspi; M L Baltz; A Feinstein; E A Munn; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

8.  Serologic evaluation of clinical and subclinical secondary hepatic amyloidosis in rhesus macaques (Macaca mulatta).

Authors:  Jamus G MacGuire; Kari L Christe; JoAnn L Yee; Alexis L Kalman-Bowlus; Nicholas W Lerche
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

9.  Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis.

Authors:  H M Falck; C P Maury; A M Teppo; O Wegelius
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-30

10.  Serum amyloid A protein (SAA) subtypes in acute and chronic inflammatory conditions.

Authors:  C P Maury; C Ehnholm; M Lukka
Journal:  Ann Rheum Dis       Date:  1985-10       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.